Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 12/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4443035 | 0.86 | NSD2 (0.77) | NSD2CYP19A1NPY5R | |
| Hydrochloric Acid SCHEMBL4448179 | 0.85 | NSD2 (0.78) | NSD2CYP19A1NPY5R | |
| SCHEMBL4483905 | 0.85 | NSD2 (0.69) | NSD2CDK2MCL1KDM4E | |
| SCHEMBL4477881 | 0.84 | NSD2 (0.51) | NSD2CDK2MCL1FABP4KDM4E | |
| SCHEMBL4470448 | 0.81 | NSD2 (0.57) | NSD2CYP19A1FABP4 | |
| SCHEMBL4445014 | 0.81 | NSD2 (0.51) | NSD2CYP19A1FABP4 | |
| SCHEMBL4494199 | 0.80 | CYP19A1 (0.58) | NSD2CYP19A1MCL1FABP4 | |
| SCHEMBL4445813 | 0.79 | NSD2 (0.73) | NSD2NPY5RMCL1 | |
| SCHEMBL4478227 | 0.79 | CYP19A1 (0.61) | CYP19A1 | |
| SCHEMBL4445387 | 0.78 | NSD2 (0.68) | NSD2NPY5RKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | claimed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | claimed |
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | OGG1, HDAC1, BCL2A1 | NSD2 639/4885CYP19A1 552/4885CDK2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.